Look after the COVID‐19 pandemic: Mortality rates among patients with rheumatic diseases

Abstract

AimSevere Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection may have a more severe course in patients with underlying disease or who have had immunosuppression. In this study, it was aimed to determine the frequency of coronavirus disease 2019 (COVID‐19) and the mortality rates related to COVID‐19 among patients with rheumatic disease.MethodsThe patients who were followed up with rheumatic disease in the rheumatology outpatient clinic in a tertiary hospital were retrospectively assessed if they had COVID‐19 infection or not between March 2020 and January 2022.ResultsA total of 10 682 patients were evaluated. There were 2928 (27.4%) COVID‐19‐positive and 7754 (72.6%) COVID‐19‐negative patients. The mean age of COVID‐19‐positive patients was 46.2 ± 14.6 years, and 65.8% were female. Forty‐two (1.4%) patients died due to COVID‐19. Among COVID‐19‐negative patients, 192 patients died. The most common rheumatic disease among patients with COVID‐19 was spondyloarthritis (SpA) (30.4%). Corticosteroids were the most common treatment agent in COVID‐19‐positive patients regardless of mortality. Thirty‐one (73.8%) patients were receiving corticosteroids, and 35 (83.3%) patients were receiving immunosuppressive agents among patients with mortality. According to the logistic regression analysis, older age, male gender, and receiving corticosteroid, hydroxychloroquine, mycophenolate mofetil, tofacitinib, rituximab, and cyclophosphamide were found to be related to increased mortality.ConclusionCOVID‐19 is a serious infection and the current study emphasized that patients with rheumatic diseases had increased mortality rates, particularly in patients who were old, male, and on immunosuppressive treatments.